0.652
-0.02 (-2.53%)
| Previous Close | 0.669 |
| Open | 0.660 |
| Volume | 239,426 |
| Avg. Volume (3M) | 6,644,868 |
| Market Cap | 29,061,482 |
| Price / Sales | 2.42 |
| Price / Book | 15.18 |
| 52 Weeks Range |
| Profit Margin | -63.52% |
| Operating Margin (TTM) | -7.46% |
| Diluted EPS (TTM) | -1.31 |
| Quarterly Revenue Growth (YOY) | -11.20% |
| Total Debt/Equity (MRQ) | 300.69% |
| Current Ratio (MRQ) | 0.810 |
| Operating Cash Flow (TTM) | 3.02 M |
| Levered Free Cash Flow (TTM) | 5.51 M |
| Return on Assets (TTM) | -2.38% |
| Return on Equity (TTM) | -138.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Harvard Bioscience, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 0.5 |
| Average | 0.33 |
|
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 8.27% |
| % Held by Institutions | 69.66% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth |
| 17 Dec 2025 | Announcement | Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |